NCT06577090Phase 2Active not recruiting

Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo

Study sponsor: Skye Bioscience, Inc. · SKYE

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Primary completion2026-11-20Estimated
Enrollment · participants136Actual
Source updated2026-01-14Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Percent change in body weight (main study) Measure: Nature, frequency and severity of AEs (study extension) Measure: Part C - The nature, frequency, and severity of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs) and adverse events of special interest (AESIs)

+ After

Measure: Percent change in body weight (main study) Measure: Nature, frequency and severity of AEs (study extension)

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

152 participants (planned)

+ After

136 participants (actual)

Check registry source

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Percent change in body weight

+ After

Measure: Percent change in body weight (main study) Measure: Nature, frequency and severity of AEs (study extension) Measure: Part C - The nature, frequency, and severity of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs) and adverse events of special interest (AESIs)

Planned enrollment increased by 32 participants

− Before

120 participants (planned)

+ After

152 participants (planned)

Primary completion date changed

− Before

Aug 2025

+ After

20 Nov 2026

Check registry source